Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 25Myelodysplastic Syndromes 8Advanced Solid Tumors 8Myeloproliferative Disorders 5Leukemia, Myelomonocytic, Chronic 5Neoplasms 4Multiple Myeloma 4Carcinoma, Non-Small-Cell Lung 4Advanced Solid Tumour 4Advanced Solid Tumor 4Small Cell Lung Carcinoma 3Recurrence 3Ovarian Neoplasms 3Lung Neoplasms 3Leukemia, Monocytic, Acute 3Triple Negative Breast Neoplasms 2Thrombocythemia, Essential 2Squamous Cell Carcinoma of Head and Neck 2Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Neoplasm Metastasis 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelomonocytic, Acute 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Biliary Tract Neoplasms 2Advanced Malignant Solid Tumor 2Advanced Lung Cancer 2

Interventions

ruxolitinib 6fludarabine phosphate 2Whole-Body Irradiation 2Tacrolimus 2Specimen Handling 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Injections 2Cyclophosphamide 2Busulfan 2Biopsy 2veliparib 1piperine 1iadademstat 1fludarabine 1fedratinib 1demethoxycurcumin 1decitabine and cedazuridine drug combination 1bomedemstat 1Transplantation 1Topotecan 1Stem Cell Transplantation 1Sirolimus 1Resistance Training 1Radiotherapy 1N(4)-oleylcytosine arabinoside 1Methotrexate 1Melphalan 1Liposomes 1INCB057643 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Thrombocythemia, Essential × Injections × 90 days × Clear all
NCT03878199 2026-04-24

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
12 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT04282187 2026-03-16

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

University of Washington

Phase 2 Recruiting
25 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡